Zacks Research Issues Negative Forecast for Perrigo Earnings

Perrigo Company plc (NYSE:PRGO) – Zacks Research decreased their Q1 2028 earnings estimates for shares of Perrigo in a research report issued to clients and investors on Wednesday, August 26th. Zacks Research analyst Team now expects that the company will earn $0.49 per share for the quarter, down from their prior forecast of $0.70. The consensus estimate for Perrigo’s current full-year earnings is $2.18 per share.

Other equities research analysts have also issued reports about the company. Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo Price Performance

Shares of PRGO opened at $14.35 on Friday. Perrigo has a 52 week low of $9.23 and a 52 week high of $23.98. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -1.15, a PEG ratio of 1.69 and a beta of 0.51. The stock has a 50 day moving average of $11.40 and a 200-day moving average of $11.42.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.11. Perrigo had a positive return on equity of 11.25% and a negative net margin of 41.85%.The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company earned ($0.06) earnings per share. Perrigo’s quarterly revenue was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be given a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 8.1%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio is presently -9.27%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Perrigo by 7.9% during the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after acquiring an additional 1,101,154 shares during the period. Bank of America Corp DE lifted its position in Perrigo by 25.5% in the 1st quarter. Bank of America Corp DE now owns 1,568,598 shares of the company’s stock valued at $16,847,000 after purchasing an additional 318,248 shares during the last quarter. Thompson Siegel & Walmsley LLC lifted its position in Perrigo by 28.4% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock valued at $64,848,000 after purchasing an additional 1,029,770 shares during the last quarter. Gamco Investors INC. ET AL boosted its stake in Perrigo by 29.7% during the 1st quarter. Gamco Investors INC. ET AL now owns 1,397,866 shares of the company’s stock valued at $15,013,000 after purchasing an additional 320,081 shares during the period. Finally, Empowered Funds LLC grew its position in Perrigo by 41.6% in the 1st quarter. Empowered Funds LLC now owns 511,872 shares of the company’s stock worth $5,498,000 after purchasing an additional 150,438 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

More Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to $2.16 from $2.10, just below the broader consensus estimate of $2.20. It also increased its Q2 2028 estimate to $0.67 from $0.66 and lifted its Q4 2027 forecast to $0.84 from $0.72.
• Neutral Sentiment: Perrigo said Interim President and CEO Albert Manzone and CFO Eduardo Bezerra will meet with investors at the Barclays Global Consumer Conference on September 10. The event could provide updates on strategy, demand trends and the company’s outlook, but no new financial guidance was announced. Perrigo to Attend the Barclays Global Consumer Conference
• Neutral Sentiment: Zacks’ value-focused commentary comparing Perrigo with Neogen and assessing whether PRGO is attractive for value investors may support investor interest, but it does not represent a new recommendation or a material change in company fundamentals. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Zacks made broad downward revisions to future earnings: FY2027 EPS fell to $2.29 from $2.50, Q1 2027 declined to $0.47 from $0.60, Q2 2027 to $0.47 from $0.58, and Q3 2027 to $0.52 from $0.60. FY2028 EPS was also reduced slightly to $2.70 from $2.72.
• Negative Sentiment: Near-term estimates were cut as well, with Q3 2026 EPS lowered to $0.59 from $0.64, Q4 2026 to $0.64 from $0.72, and Q1 2028 to $0.49 from $0.70. These revisions suggest analysts see weaker or more uncertain earnings momentum ahead, likely outweighing the isolated FY2026 upgrade.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.